|Bid||2.0200 x 1200|
|Ask||2.0400 x 1300|
|Day's Range||1.9700 - 2.0620|
|52 Week Range||0.8200 - 6.0200|
|Beta (5Y Monthly)||1.54|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Multi-center trial to assess the safety and efficacy of pelareorep-atezolizumab combination therapies across multiple GI cancer indicationsTreatment aimed at 4.8M global GI cancer cases annually1 and the approximately 80% of GI cancer patients who do not respond to immune checkpoint inhibitor therapy currentlyStudy builds on prior early findings of greater than 90% clinical benefit in colorectal and greater than 80% increase in progression-free survival in pancreatic cancer patientsSAN DIEGO, CA and CALGARY, AB, Oct.
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the appointment of Richard Vile, Ph.D., to its Scientific Advisory Board (SAB). Dr. Vile, a Professor of Immunology at the Mayo Clinic, brings expertise as a key opinion leader (KOL) in oncolytic viruses and adoptive T cell therapies to the Oncolytics SAB.
Just because a business does not make any money, does not mean that the stock will go down. By way of example...